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2Abstract
Patients with chronic kidney disease (CKD) experience an imbalance between oxygen
reactive species (ROS) production and antioxidant defenses leading to cell and tissue damage.
However, it remains unclear in which stage of renal insufficiency the redox imbalance
becomes more profound. The aim of this systematic review was to provide an update on
recent advances in our understanding of how the redox status changes in the progression of
renal disease from pre-dialysis stages 1 to 4, to end-stage 5 and whether the various
treatments and dialysis modalities influence the redox balance. A systematic review was
conducted searching PubMed and Scopus by using the Cochrane and PRISMA guidelines. In
total, thirty nine studies met the inclusion criteria and were reviewed. Even from an early
stage, an imbalance in redox status is evident and as the kidney function worsens it becomes
more profound. Hemodialysis therapy per se seems to negatively influence the redox status by
the elevation of lipid peroxidation markers, protein carbonylation and impairing erythrocyte
antioxidant defense. However other dialysis modalities do not so far appear to confer
advantages. Supplementation with antioxidants might assist, and should be considered as an
early intervention to halt premature atherogenesis development at an early stage of CKD.
3Introduction
In the literature there is strong evidence suggesting that uremia, which develops in tandem
with renal deterioration, is accompanied by an enhanced state of oxidative stress, which in
turn is associated with higher risk of developing cardiovascular disease (CVD) and mortality
[1]. The presence of oxidative stress in uremic patients is manifested by increases in the levels
of several oxidative damage markers and by a parallel reduction in their antioxidant defense
capacity [2, 3]. In chronic kidney disease (CKD) this state of redox imbalance is linked to
additional pathological complications that CKD patients present with, such as malnutrition,
anemia, and cardiovascular disease including atherosclerosis [2, 4, 5].
CVD remains the leading cause of death in CKD patients, with oxidative stress being
implicated in the onset and the development of atherosclerosis, via mechanisms such as
oxidation of low-density protein (LDL) [6]. It is reported that levels of lipid and protein
peroxidation markers, such as malondialdehyde (MDA), advanced glycosylation end-product
(AGE), and advanced oxidation protein products (AOPPs) are elevated in CKD patients, with
some studies indicating a correlation between some lipid peroxidation markers and intima-
media thickness [7-9]. Lipid peroxidation could be described as a process where oxidants,
such as free radicals, assault lipids especially in membranes [10]. Additionally, regarding
erythrocyte membrane integrity, modifications due to oxidation and the increased membrane
rigidity could play a key role in shortening erythrocyte half-life compounding the
development of anemia [11], which characterizes these patients. Furthermore, a disturbance
of the Glutathione antioxidant system, including overall compromised blood levels of reduced
glutathione (GSH), increased oxidized glutathione (GSSG), and increased erythrocyte
glutathione peroxidase (GPx) and glutathione reductase (Gr-reductase) activities, has been
reported in CKD [12, 13]. Likewise, a decrease in catalase (CAT), a key enzyme for the
detoxification of hydrogen peroxide and organic hydroperoxide, accompanied by increased
nitric oxide (NO) inactivation and protein nitration by reactive oxygen species (ROS) [14],
have been linked to the pathogenesis of CKD related hypertension, via a dysregulation of NO
function. Further, at the level of the kidney per se, redox disturbances can have direct effects
of the afferent arteriole function (e.g. vasoconstriction) and tubuloglomerular feedback (e.g.
affecting macula densa cell function or signaling), contributing to the development of
hypertension [15].
A variety of mechanisms have been implicated in the generation of oxidative stress in
uremic patients, such as antioxidant deficiency, chronic inflammation [16, 17] including
advanced glycation mediated disturbances of glomerular homeostasis as disease progresses
[18]. In addition, for the end-stage patients (ESRD), neutrophil activation during
4hemodialysis (HD) therapy [19] and dialysis treatment per se contribute to the increase of
oxidative damage observed in patients with CKD [20-22]. Four main factors have been
proposed to be responsible for the harmful effects of oxidative stress in patients under HD :
the uremic milieu, the HD treatment per se, the hemoincompatibility of dialysis system and
the concomitant drug treatment [23].
Until today most studies examining the redox status in CKD patients focused on the
end stage of the disease. However, it remains unclear when during disease progression the
redox imbalance manifests itself, and which one of its components, defense capacity or ROS
overproduction, becomes critical first. Thus the aim of this systematic review was to provide
an update on recent advances in our understanding of how the redox status changes in the
progression of CKD from pre-dialysis stages (1 to 4), to end-stage 5, and whether various
treatments positively or negatively influence the balance between oxidant and antioxidant
mechanisms.
Methods
The current review includes original studies reporting on oxidative stress markers in
CKD patients (including pre-dialysis and ESRD, on hemodialysis or peritoneal dialysis).
PubMed and Scopus databases were searched by two reviewers according to the Cochrane
and PRISMA guidelines [24, 25], in order to identify publications in English related to
oxidative stress in blood of uremic patients. A comprehensive literature search was conducted
from September 2015 until November 2015. The time frame the studies were searched was
from January 1995 until November 2015. Studies were selected using inclusion and exclusion
criteria. We included studies that met the following criteria: they assessed oxidative stress
markers in the blood of uremic patients (hemodialysis, peritoneal dialysis, or pre dialysis);
they used blood samples; they addressed randomized control trials, controlled trials, or
clinical trials designed to evaluate oxidative stress in blood of uremic patients on HD, PD
therapy or not; they were written in English. Exclusion criteria included: studies of patients
with untreated cardiovascular disease, metabolic syndrome, hypeparathyroidism and
hypertension, kidney transplantation, atherosclerosis and cancer. Moreover, case studies,
dissertations, letters, studies published only in abstract form and studies that were unavailable
in English were excluded from the analysis as well. Firstly, titles and abstracts were assessed,
followed by assessment of full text copies of the articles. The initial screening was followed
by an extra search in order to identify only the studies that dealt with oxidative stress in
uremic patients.
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The literature search identified a total of 80 articles. Of these, 39 studies met the
inclusion criteria, which were set in this review (Figure 1). Articles were excluded for the
following reasons: 23 studies correlated CKD with factors which were irrelevant to oxidative
stress and thus were out of our interest, or dealt mainly with other comorbidities such as
diabetes, cardiovascular disease, hyperparathyroidism. One study examined acute chronic
liver disease instead of CKD. Seven studies did not measure oxidative stress biomarkers, to
three, despite efforts, we gained no access, one was non-randomized study, one was not
written in English and 5 did not have detailed methodology.
From the included studies, three evaluated oxidative stress markers in blood of pre-
dialysis patients compared to healthy individuals and four studies dealt with several types of
interventions in these patients. Ten studies examined oxidative stress in HD patients
compared to healthy individuals and eight studies assessed oxidative stress before and after
HD session. Seven studies reported some interventions affecting the redox status of HD
patients. Two studies examined oxidative stress biomarkers in patients undergoing other types
of HD and one study reported and intervention that took place in these patients. One study
examined simultaneously oxidative stress in pre-dialysis, HD dialysis and PD dialysis
compared to healthy individuals. One study examined oxidative stress markers in pre-dialysis
patients compared to controls, in HD patients compared to controls and in HD patients before
and after an HD session. Two studies evaluated oxidative stress in HD patients compared to
controls and in HD patients before and after an HD session. For these reasons data from these
last four studies were included in more than one Table.
Analysis and Discussion
We used the CKD severity staging reported by the authors themselves, or when not
available, to facilitate discussion, we adopted the definition of CKD stages based on measured
or estimated Glomerular Filtration Rate (GFR), according to KDIGO 2012 guidelines for
CKD [26]. According to these guidelines there are five stages, where kidney function is
considered as normal in stage 1 and is progressively reduced as progressing from stages 2 to
5. Each section reporting on the analysis of our systematic review’s findings concludes with
discursive commentary using relevant information from other literature.
6Pre-dialysis patients and redox status
Only 5 studies examined the redox status in pre-dialysis CKD patients. These studies
evaluated the oxidative damage as it was assessed by the lipid peroxidation biomarker MDA
and the pro-oxidant enzyme xanthine oxidase (XO), as well as the antioxidant defense as it
was assessed by GSH concentration and superoxide dismutase (SOD), and CAT and GPx
activities (Table 1).
Regarding lipid peroxidation damage, four studies measured MDA levels in plasma
or red blood cells (RBC) of CKD patients. Specifically, Peuchant et al 1996 [11] found
increased levels of RBC free MDA in 16 patients with stage - 5 CKD compared to age-
matched controls. Additionally, Sahni et al [27] found increased RBC MDA levels in 60
patients with severe (near stage 5) and in 85 patients with moderate CKD compared to age-
matched controls, with RBC MDA levels being significantly higher in the severe compared to
moderate disease group. MDA levels were also evaluated in plasma and Papavasiliou et al
[28] found them increased in 23 patients with stage 3 - 5 CKD, compared to age-matched
controls. In the same study 13 patients on stages 1 - 2 CKD, exhibited a tendency for higher
MDA levels compared to healthy controls but values’ differences did not reach statistical
significance. In contrast, stages 1 - 2 patients, exhibited significantly lower MDA levels
compared to the stages 3-5 CKD patients [28]. Bober et al 2010 [29], measuring TBARS
(which are expressed as equivalents of MDA levels) reported higher plasma levels in 21 pre-
dialysis CKD patients on conservative treatment and age-matched healthy controls. However
it was not clear if results were statistically significant, nor was there information on the pre-
dialysis stage of those patients. Choi et al [30] reported that xanthine oxidase (XO) activity
was increased in the plasma of 16 patients with stage - 4 CKD (almost ~1.5 fold compared to
values of healthy individuals), indicating an increase in free radicals generation.
Regarding antioxidant defense in pre-dialysis patients, four studies evaluated several
antioxidant molecules and enzymes. Sahni et al 2012 [27] found that the increase in lipid
peroxidation biomarkers in pre-dialysis patients was accompanied by a reduction in
antioxidant enzymes activity being reflected by reduced GSH, SOD and CAT levels in both
severe and moderate pre-dialysis patients, compared to healthy individuals [27]. On the other
hand in the study of Bober et al [29] higher levels of GSH were found in CDK patients
compared to healthy individuals but as it was referred above the stage of patients disease was
not mentioned in the study. However, a study by Peuchant et al [11] did not observe any
changes in the activities of the free radical scavenging enzymes GPx, SOD and CAT in the
erythrocytes of CKD patients compared to healthy individuals. Significantly higher levels of
erythrocytes GPx activity have also been observed in both patients with stage 1-2 and 3-5
7CKD compared to healthy subjects, by Papavasileiou et al [28], with EPO treatment
preventing the reduction in enzyme activity observed in patients not receiving EPO.
The results of these five studies concur to that CKD progression leads gradually to a
state of increased ROS production, which is reflected by the elevated levels in markers of
lipid damage and the decrease in the concentration of antioxidant molecules and activity of
antioxidant enzymes. As mentioned already, lipid peroxidation affects erythrocyte half-life, as
its excess could overcome cell repair capacity [10]. According to Peuchant et al [11] their
results could be attributed to the fact that patients with CKD have decreased erythrocytes
survival. Thus erythropoiesis is activated and could increase RBC precursors and enzymatic
synthesis as well as consumption of antioxidant enzymes. Moreover, additional mechanisms
are implicated in the enhanced lipid peroxidation in CKD such as the reduction in glucose-6-
phosphate dehydrogenase activity, which leads to a decrease in NADPH and GSH
concentrations and vitamin E deficiency [31-33].
Undeniably, a compromised antioxidant intake may contribute to the above
observations, as pre-dialysis patients need to adhere to specific diet guidelines and restrictions
[27]. Indeed, intake of exogenous antioxidant vitamins, such as vitamins A and C, and
glutathione precursors, were found to be at lower levels in pre-dialysis patients compared to
healthy subjects, with nutritional intakes worsening as CKD became more severe, and evident
negative correlations between antioxidant intakes with oxidative stress levels [27].
Interventions in pre-dialysis patients and redox status
Several interventions to correct for anemia, counteract inflammation and supplement
nutrition have become part of clinical and peri-clinical care in addition to appropriate
pharmacological therapy, and could affect redox balance. At the pre-dialysis stage we located
only four references that fulfilled our criteria.
Ganguli et al [34], reported that various forms of intravenous iron [low molecular
weight iron dextran (ID), sodium ferrigluconate complex, in sucrose (SFGC), and iron
sucrose (IS)] at clinically used doses, resulted in elevated MDA levels, measured immediately
after the iron transfusion period [34]. Marsillach et al [35] evaluated the 6-months effects of
EPO treatment, together with iron treatment (SFGC or IS), measuring antibodies against ox-
LDL, and paraoxonase (PON1) activity and concentration which is assumed to play an
important role in oxidized lipid degradation. Results revealed decreased levels of ox-LDL
antibodies and increased serum PON1 activity despite the iron treatment [35]. However, in
addition to an effect of EPO, large differences in baseline LDL and ferritin levels between the
two studied cohorts can explain the conflicting reports.
8Ramos et al [36] investigated whether the administration of mixed tocopherols and
lipoic acid for 2 months could modify oxidative stress indices in CKD patients. However, no
significant changes in F2- isoprostanes and protein thiols concentrations were observed in
these patients compared to matching controls. As the authors discussed, the sample size, the
intervention’s duration, the dose or the composition of antioxidants all could probably have
been biologically ineffective in altering the redox status of this particular patient population
[36]. Moreillon et al [37] assessed the antioxidant effects of two types of herbal supplements
curcumin and boswellia serrata, on GPx levels, after 8 weeks supplementation. Despite the
increase in plasma GPx levels in the treatment group, results were not statistically significant.
Perhaps the duration of supplementation was not sufficient enough for the small sample size
used [37] to detect an effect.
Data in non-CKD patients suggest that higher doses of vitamin E supplementation
may be necessary to observe measurable changes in redox status. For example, in
hypercholesterolemia patients, after 4 months of Vitamin E supplementation, there was a
decrease in F2-isoprostane concentration, only with the high doses of 1600 and 3200 IU/day
[38]. Herbal supplements such as curcumin [39] and Boswellia serrata, [40] [41], are known
for their anti-inflammatory and antioxidant characteristics, for example in patients with colitis
[40] [41]. While one study [37] did not report an effect future studies could explore further
their possible contribution to ameliorate oxidative stress in pre-dialysis patients via nutritional
strategies.
Apart from the impaired nutritional status, CKD patients are also characterized by
iron deficiency and depletion of iron storage. Although the administration of intravenous iron
is fully recommended in these patients for anemia correction, the short and long-term safety
of this administration remains unclear. According to Bishu and Agarwal [42] intravenous iron
administration contributes to elevated oxidative stress and endothelial dysfunction in CKD
patients. Moreover, according to Himmelfarb et al [43] endothelial dysfunction plays a key
role in the pathogenesis of atherosclerosis in CKD patients and oxidative stress is implicated
in this pathway. It can be surmised that a treatment meant to correct anemia, iron
supplementation, could exacerbate atherosclerosis by promoting oxidative stress. The two
studies supplementing iron to pre-dialysis patients reviewed above, Ganguli et al [34], and
Marsillach et al [35] reported conflicting effects of iron on lipid peroxidation. However the
interaction of iron to circulating LDL cannot be underestimated (i.e. a systemically
atherogenic environment) while at the same time EPO appears to confer an antioxidant
advantage (as shown earlier by Papavasileiou et al [28], that EPO treatment prevented the
reduction in erythrocytes GPx activity observed in patients not receiving EPO).
9HD patients and redox status
Overall, 14 studies were found, which examined the oxidant and antioxidant status in
HD patients and compared it with healthy subjects (Table 2). These studies evaluated
oxidative damage as it was assessed by lipid peroxidation markers MDA and isoprostanes,
and protein carbonylation as it was assessed by protein carbonyls and advanced oxidation
protein products (AOPPs). Moreover, in these studies, the antioxidant defense was evaluated
by measuring the antioxidant molecules sulfhydryl groups and GSH, the antioxidant enzymes
SOD, GPx and Gr reductase and the total antioxidant capacity markers oxygen radical
absorbing capacity (ORAC), Trolox equivalent antioxidant capacity (TEAC) and total
antioxidant capacity (TAC).
More specifically, in seven studies, increased levels of MDA [29, 44-49] were
observed in HD patients compared to healthy individuals, reflecting extensive lipid damage.
Sommerburg et al [44], reported that HD patients who received long-term EPO treatment
showed decreased levels of lipid peroxidation compared to patients who did not receive EPO
treatment. Furthermore, Dolegowska et al [50] reported a significant increase in plasma
isoprostanes (8-iPF2a-III) concentrations, in HD patients.
Regarding protein damage, levels of protein carbonyls were also found to be elevated
in HD patients in four studies [49, 51-53]. In addition, advanced oxidation protein products
(AOPPs) were found to be in high levels in HD patients in two studies [46, 53] however they
were reported to be no different than control in one study [54]. In the latter study of Fragedaki
et al [54] patients were on dialysis for a shorter period (an average of 3 years) than the other
studies [46, 53] a fact that could affect AOPPs levels. Finally, Choi et al [30] reported
increased XO activity in HD patients compared to healthy subjects (by almost 3 fold); with
XO activity being also higher (by 2.1 fold) than pre-dialysis patients. Taking into
consideration the above results, there is evidence of extensive oxidative damage to total
protein content and lipids in HD patients.
Regarding the antioxidant capacity in HD patients, the literature provides differing
results. Sakata et al reported a significant increase in ‘global’ antioxidant capacity markers,
such as ORAC and TEAC [46]. On the other hand, Dimitrijevic et al [47] reported a
significant decrease in total antioxidant capacity (TAC) of HD patients compared to controls
while decreased albumin levels were also observed. It should be noted that these global
antioxidant capacity markers do not represent innate antioxidant capacity but rather represent
global availability of free radical scavenging compounds, whose levels are greatly affected by
nutrition.
Moreover, the activity of the free radical scavenging enzymes plasma GPx (GSH-Px)
and SOD was found to be significantly decreased in HD patients [48]. GPx has been
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identified in two forms: cellular or cytosolic (GPx-1) which is presented in red blood cells and
the cytosol of almost all tissues, and extracellular (GPx-3) in the plasma, with selenium (Se)
being a basic structural component in both forms, [48], an element also affected by nutrition.
Additionally, Gr Reductase activity was found to be significantly higher in HD patients
compared to healthy subjects [55], probably reflecting the organism’s efforts to activate the
antioxidant defenses. Likewise, that study also reported increased GSH total blood
concentrations in the HD patients studied [55]. On the other hand, two studies [47],[53]
reported a large reduction of free sulfhydryl groups levels in HD patients, measured in
plasma.
All the results concur to that HD treatment seems to contribute to augmented
oxidative stress. Most of the studies observed increased levels of protein and lipid damage in
HD patients, which were measured with established biomarkers. As it appears, HD treatment
causes an enhanced rate of LDL oxidation, which leads to the development of atherosclerosis,
as reflected in elevated blood MDA levels. One mechanism is that the uremic milieu and the
HD process per se stimulate neutrophils, a procedure known as “neutrophil burst”, which
directly or indirectly results to hydrogen peroxide production. This is then converted to
hypochlorous acid, which in turn contributes to the oxidation of plasma proteins and LDL,
assaulting their membranes [46, 56]. Furthermore, as it was referred above, lipid peroxidation
negatively affects erythrocyte half-life leading to decreased survival and manifestation of
anemia. EPO appears to help as Sommerburg et al [44] reported that HD patients who
received long-term EPO treatment presented decreased levels of lipid peroxidation. These
results in HD concur with findings in pre-dialysis patients, where also EPO appears to confer
an antioxidant advantage [28], by preventing the reduction in erythrocytes GPx activity
observed in patients not receiving EPO. Moreover, while erythropoiesis is, in a healthy
individual, stimulated by ROS, as discussed by Migliaccio, erythropoiesis also counteracts
circulating ROS levels via increases in available catalase and possibly other antioxidant
enzymes [57]. Further on the atherosclerosis mechanism, the presence of F2 –isoprostanes has
been determined in human atherosclerotic lesions [58]. F2 –isoprostanes are created during the
non-enzymatic peroxidation of arachidonic acid bound up with phospholipids of cells
membranes and lipoproteins [59-61], and they are considered sensitive and specific indicators
of oxidative stress intensity in vivo [58, 62]. Given reports, such as [50], of a significant
increase in plasma isoprostanes in HD patients, the link between oxidative stress and CVD in
HD patients is further highlighted.
The results on the antioxidant capacity of HD patients are not as straightforward to
explain. Caloric restriction (without essential nutrient deficiency) in rats has been shown to
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result in decreased antioxidant capacity (ORAC) [63]. CKD patients however, are subject to
both caloric restriction and deficient antioxidant intakes [23]. Differences between studies
reporting on HD antioxidant capacity could be thus attributed not only to adaptive
mechanisms, due to years in dialysis and comorbidities, but also to dietary restrictions and
inter-individual differences in antioxidant nutritional intakes, as already reported in pre-
dialysis patients [27]
Additionally, the hemodialysis process per se may compromise key nutrient and trace
mineral levels as highlighted with regards to levels of Se a basic component of GPx. Guo et al
[48] reported that HD patients presented with lower plasma Se concentrations than healthy
subjects and this could be attributed to either impaired diet/absorption or increased loss of Se
during dialysis treatment [64]. Additionally, taking into account that the kidney is the main
site of plasma GPx synthesis and is also capable of Se accumulation [65], that the levels of
both Se and GPx are reduced in ESRD patients is not unexpected. A similar explanation could
be also given for the significant reduction in plasma SOD activity observed in HD patients,
linked to Zn availability, which is a structural element of SOD and whose levels tend also to
be reduced in renal insufficiency [66].
Regarding GSH depletion in HD patients, many mechanisms have been proposed.
According to Yawata et al. [31], an obstruction to the pentose phosphate pathway leading to
impaired production of NADPH occurs in patients with ESRD. As a result, Gr Reductase
cannot recycle GSSG back to GSH using NADPH as electron source [31]. Notwithstanding,
in many studies, GR activity has been found to be increased or in normal levels [12, 55, 67,
68]. Thus, GSH depletion could be alternatively attributed either to a diminished GSH
synthesis and/or to an increased GSH degradation, since its precursors cystine, glutamate and
glycine could be normal or elevated in patients’ blood [69].
Redox status before and after the HD treatment
The hemodialysis treatment can affect patients’ redox status, and our systematic
literature search revealed 11 studies which examined the possible contribution of HD
treatment on redox imbalance (Table 3). Three studies indicated that HD treatment per se
augments lipid peroxidation, assessed by MDA [29, 70] and F2 – isoprostanes levels [50] and
induces protein damage, assessed by protein carbonylation [53]. However, there were studies,
which did not observe any significant changes in lipid peroxidation (unchanged MDA levels)
[71, 72], F2-isoprostanes levels [73] and ox-LDL levels [74] following the HD process [71-
74]. Moreover, in the Malindretos et al study, oxidized LDL levels didn’t significantly change
after HD treatment, neither intravenous iron administration during HD changed its
concentration following HD [74].
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Regarding antioxidant capacity after completion of HD therapy, there are conflicting
findings. Two studies reported that the levels of GSH and the activities of Gpx and Gr-
reductase increased after HD therapy [55, 75]. However, there were three studies in younger
patients, which observed reduced levels of GSH [29, 70], reduced GPx activity [70] and
reduced TAS levels [70, 76] following HD.
Ogunro et al [70], evaluated the effects of cellulose and polysulfone membranes,
which are the most commonly used types, on redox status in chronic HD patients. SOD
activity was significantly reduced in both cellulose and polysulfone membrane dialysis.
Regarding other antioxidant biomarkers evaluated in this study, both types of membranes
caused changes to same direction but not significant in all cases. Specifically, CAT activity
was significantly increased only in polysulfone membrane while GPx activity was reduced in
both types but not significantly. Additionally, TAS and GSH levels were significantly
reduced after cellulose membrane HD while the reductions were not significant in
polysulfone membrane users. Lastly, following HD treatment, MDA levels were increased in
both types but the change was significant only in cellulose membrane.
On the other hand, Ward et al [53], did not find differing responses to the use of
polysulfone or cellulose membranes on protein oxidation. These HD patients demonstrated
already high plasma protein carbonyls and AOPP concentrations compared to normal values,
before HD treatment. With HD, using either membrane, protein carbonyls increased
significantly over the course of HD and remained significantly elevated for the post-dialysis
period, indicating a worsening in protein oxidative damage. Dialysis had no effect on AOPP
levels and their values remained significantly higher than normal after dialysis. Perhaps
counterintuitively, in that study, following HD a significant increase in plasma free sulfhydryl
groups concentrations was found (levels essentially corrected to the levels of normal values),
for both membranes used [53].
Bober et al [29], assessed the effects of glucose content in the dialyzing fluid on RBC
antioxidant capacity. They found that glucose concentrations of about 5.6 mmol/l resulted in
an augmentation of the hexose monophosphate cycle (HMP) in erythrocytes and accordingly
benefited the antioxidant system. Furthermore, the group who received the glucose-free HD
treatment presented with increased TBARS concentration after the treatment [29]. According
to the authors, this probably occurred, because the free radicals produced during the glucose-
free HD session could not be neutralized through the non-enzymatic pathway at a satisfactory
rate [29]. In the cross-sectional study of Dolegowska et al [50], there were no significant
differences, either pre or after HD treatment, in 8-iPF2a-III levels in RBC membranes of HD
patients treated with glucose or glucose-free dialyzing fluids. Still, they reported a significant
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increase of plasma 8-iPF2 -III concentration following HD in the glucose-free group (which
however started at a much lower level than the glucose treated group).
Various mechanisms have been proposed to account for the increased oxidative
damage following HD treatment. Firstly, the issue of hemoincompatibility induced by the
contact between human blood and the non-biological materials of the hemodialyzer and the
resulting effects on leukocyte and platelet activation and inflammation [20, 77, 78].
Moreover, systemic inflammation effects mediated via neutrophil activity burst resulting in
the release of ROS into the bloodstream [46, 56]. Furthermore, the role the HD process per se
in reducing plasma antioxidant defense because several antioxidant dialyzable solutes are
removed during HD.
The role of the type of dialysis membrane used is not straightforward [53, 71]. This is
probably due to the different reactions that take place in sulfhydryl groups and protein
carbonyl formation. Possibly, protein sulfhydryl groups are oxidized reversibly through small
molecules oxidants, which can be removed by dialysis process, while AOPP and protein
carbonyls may represent a chronic state of irreversible oxidative damage [53].
With regard to dialyzing fluid composition, it could be generally concluded that
glucose has a beneficial effect on the antioxidant properties of RBC and protects them by
decreasing the risk for hemolysis [29, 50].
Intervention in HD
Three studies examined the effects of Vitamin C administration on redox status of
HD patients. Fumeron et al [77] reported that oral administration of 250 mg Vitamin C three
times per week for two months, could not either increase GSH or reduce protein carbonyls
levels. Washio et al [78], found that oral administration of Vitamin C for 3 months, ranging
from low (200 mg) to high dose (1000 mg) could not suppress the enhancement of Cu/Zn-
SOD expression, an oxidative stress marker. On the other hand, Tarng et al [79] found that
intravenously administration of 300 mg Vitamin C for 8 weeks decreased significantly 8-
OHdG contents in cellular DNA of lymphocytes. Moreover in the same study vitamin C
significantly reduced intracellular ROS production of lymphocytes of patients on HD [79].
Regarding Vitamin E, another important antioxidant substance, Smith et al [73]
examined the effects of 400IU administration for 2 months, on redox status of 11 HD patients.
The elevated free F2-isoprostane plasma concentrations were not decreased by vitamin E
supplementation. Likewise, treatment with a combination of mixed tocopherols plus αlipoic
acid (oral) for 6 months didn’t change plasma F2- isoprostane and F2- isofurane of HD
patients compared to placebo group as reported by Himmelfarb et al [80].
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A pilot study by Trimarchi et al [71] showed that the daily administration of 1,200
mg NAC for one month could significantly reduce plasma lipid peroxidation of HD patients
compared to the control group. Finally, Fatouros et al [81] reported that daily administration
of 20 mg/kg L-carnitine in 12 HD patients for 8 weeks resulted in 2,7 fold increased
GSH/GSSG ratio, a 4.5%  increase in glutathione peroxidase activity, a 19% decrease in
MDA levels and 27% decrease in protein carbonyls concentration.
Vitamin C is one of the most important water-soluble antioxidants. There is evidence
that HD patients exhibit a 30-50% decrease in Vitamin C levels after dialysis treatment, as
reviewed elsewhere [82]. Moreover, reduced Vitamin C levels in HD patients have been
associated with an increased risk for CVD morbidity and mortality [83]. However, elsewhere,
only intravenous administration was found to have a measurable beneficial effect [79]. Thus,
oral administration of Vitamin C may not be sufficient to correct its deficiency in HD.
Oral administration of Vitamin E did not decrease plasma isoprostanes in HD patients
[74, 83]. In contrast, it has been reported that long-term administration of 200 mg of Vitamin
E decreased F2-isoprostanes plasma levels in mildly hypercholesterolemic men [84].
Moreover in healthy subjects Vitamin E administration resulted in lower F2-isoprostane
concentrations in urinary samples [85]. Perhaps differences in outcomes relate to dosage and
duration of administration could explain these results, notwithstanding the augmented oxidant
production characterizing HD patients which perhaps oral administration of Vitamin E, at safe
levels for these patients, could not combat.
N-acetylcysteine (NAC) is a ROS scavenger and its administration seems to increase
glutathione concentration given that it raises intracellular levels of one of its precursors,
cysteine [86-88]. Along with L-Carnitine, these products showed promising results and
should be further examined in larger patient cohorts.
Other types of Dialysis and redox status
Our systematic literature review revealed 4 studies that examined other types of
dialysis in relation to oxidative stress and antioxidant status biomarkers (Table 4). A
metabonomics study by Choi et al [30] examined the effects of different dialysis modalities
on serum profiles of patients. XO activity levels were similar for both HD and peritoneal
dialysis (PD) patients. Still XO activity was significantly higher in PD compared to controls
and to non-dialysed uremic patients (non HD or PD) [30], perhaps justifying the need to
address it pharmaceutically (see below Interventions in PD).
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In the study of Canestrari et al [89] erythrocyte GSH levels were unchanged or
slightly increased in the patients compared to the control group while a nearly 3-fold increase
in GSSG was observed in the PD group [89]. In the same study, plasma GSH levels were
significantly decreased in the PD group compared to control group and GSSG levels were
slightly increased in PD patients [89]. Moreover, increased RBC and plasma TBARS levels
were found in PD patients compared to control group. Finally, significantly higher
erythrocyte GSH-Px activity was observed in the PD group while plasma GSH-Px activity
was similar in PD and controls [89].
Moreover, a study by Gonzales-Diez et al [90], examined and compared the effects of
haemodiafiltration (HFR) to HD with polysulfone membranes (HD-PS). The HFR group
demonstrated moderate changes in oxidative stress biomarkers and antioxidant capacity
markers, indicating that this method may in the long term preserve a more stable and balanced
redox status compared to HD-PS [90].
Interventions in PD
Imani et al [91], evaluated the effects of soy consumption (28 g/day) for 8 weeks on
oxidative stress in PD patients. Results indicated no changes in serum ox-LDL between soy
and control group of PD patients, however an improvement in thrombosis risk was reported.
The fact that the 78% of the specific peritoneal dialysis patients received Vitamin C and/or E,
could explain the lack of a measurable effect. We do consider however that such dietary
interventions as well as antioxidant interventions of adjunct pharmaceuticals need further
examination (see below).
Overall, based on the limited data reviewed so far, PD also appears to be associated
with increased oxidative stress, with the Choi et al study [30] showing PD patients to have as
high XO activity as HD patients and the Canestrari et al study [89] showing not only
increased oxidative stress but also evidence of reductions in antioxidant capacity, compared to
controls. As XO is a superoxide producing enzyme its inhibition has been viewed as a way to
reduce CVD risk (e.g. via allopurinol, [92]). To circumvent possible allopurinol’s toxicity in
renal insufficiency patients careful screening and tolerance protocols are needed [93]. A new
non-purine alternative, febuxostat, has been shown to reduce serum levels of uric acid and
levels of a marker of DNA oxidation (8-oxo-dG) following 6 month administration in HD
patients [94].
In non-CKD patients, soy consumption has been reported to improve redox status (for
example in gestational diabetes [95]). Notably, the combination of soy milk with
Lactobacillus plantarum was recently shown not only to improve redox status, vs
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consumption of plain soy milk, but also to exert a promising epigenetic effect on the DNA
repair capability of type II diabetic patients [96]. Dietary antioxidants may play a role even
before disease diagnosis, whether independently or as a component of a generally ‘healthy
lifestyle’, as an increased albuminuria (a prognostic marker for kidney disease), has been
found to be associated with reduced levels of diet-derived carotenoids in an indigenous
Australia population [97]. Such and other findings highlight the complexity and overarching
effect on redox status introduced by diet. We suspect that whether early in the disease, or
towards advanced stages (especially when CKD patients face severe nutritional restrictions,
but were at the same time, not only noxious but potentially beneficial antioxidant
intermediates as well may accumulate [98]), the role of targeted nutritional aids to reduce
systemic oxidative stress could prove crucial for the reduction of CVD and malignancies risk.
Our evaluation of the systemic effects of oxidative stress in CKD patients does not
account for the issue of kidney tissue and cell specific disturbances in redox homeostasis.
Although beyond the aim of the present systematic review we consider of interest to give
some highlights. Initial glomerular injury affects podocytes, the glomerular visceral epithelial
cells, which constitute not only the target but also the source of ROS. Bek et al 2003 [99],
using cultured mouse podocytes demonstrated that Stra13, a prostaglandin E2-induced gene,
protected the redox homeostasis in this cell type, preventing podocytes from injuries and
subsequent detrimental effects on kidney functionality. Apart from podocytes, another type of
kidney cells, known as mesangial cells are known to play an important role in CKD
progression. More specifically, angiotensin II (ANG II) stimulates proliferation of the
mesangial cells resulting in pathological changes in CKD [100, 101]. Although the exact
mechanism remains incompletely understood, Ding et al 2007 [102] reported that the ROS-
epidermal growth factor receptor EGFR-JNK pathway is involved in transducing the
proliferative effects of ANG II in cultured mesangial cells. Thus, specifically targeting the
injured kidney to ameliorate or break the vicious circle of recurrent injury, inflammation and
oxidative stress and salvage glomerular function (as suggested in [103]) holds promise.
Conclusions
The results of this systematic review indicate that oxidative stress is implicated in the
CKD pathophysiology and as the kidney function is getting worse, the redox status imbalance
becomes more profound. Even at an early disease state lipid peroxidation markers are
elevated. This premature development sets perhaps the pace for accelerated atherogenesis,
which appears to explain the profoundly negative CVD risk of end-stage patients. Thus early
interventions to combat lipid peroxidation in pre-dialysis patients need to be considered.
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At the end-stage, patients present both with overabundance of ROS and mostly
compromised antioxidant capacity. HD therapy per se seems to contribute to the oxidant and
antioxidant imbalance. Iron supplementation has a pro-oxidant role but appears largely
balanced out by appropriate EPO supplementation. The choice of dialysis membrane and
dialyzing fluid glucose content may modulate the pro-oxidant effect of HD treatment.
Moreover, antioxidant supplements may ameliorate oxidative stress levels by enhancing
antioxidants defense, however mode of administration (i.e. intravenous for Vitamin C) should
be carefully considered for efficacy. Vitamin E supplementation has been so far shown to be
ineffective in HD patients, however small studies testing NAC and L-carnitine reported
promising results.
Peritoneal dialysis did not appear to have a clear advantage over HD treatment,
despite the biocompatibility advantage, while HFR may better preserve some antioxidant
molecules. However the small number of studies in PD and HFR do not allow for safe
conclusions and further work is needed to clarify the role of dialysis modality on redox status
of ESRD patients.
Future studies addressing possible interventions to reduce the high burden of
oxidative stress in patients with CKD are needed. Such studies should be prospective,
comparative, systematically structured according to outcome, should include a large number
of patients and should have an adequately long follow-up.
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Table 1. Redox status in pre-dialysis CKD patients.
Authors Groups MDA XO GSH SOD CAT GPx
Peuchant et al
1996 [11]
a. 16 CKD patients, (age: 43.6±11.2 yr)
GFR:12.6±5.4 ml/min
b. 26 healthy subjects, (age: 43.6±11.2 yr)
RBC free MDA:
a. 3.88±2.67
b. 1.74±0.56
Total MDA:
a.10.0±9.31
b.7.85±2.82
(nmol/ml)
a.800
b.790
(U/g Hb)
a.45
b.43
(U/g Hb)
a.34
b.32
(U/g Hb)
Papavasiliou et
al 2005[28]
a.12 CKD patients, (age: 66 yr)
Creatinine clearance:23.9±6.6 ml/min
b. 11 CKD patients (age: 61 yr)
Creatinine clearance:20.2±6.5 ml/min
c. 13 CKD patients (age: 63 yr)
Creatinine clearance:87.2±7.1 ml/min
d. 15 healthy subjects (age: 59 yr)
Plasma:
a. 1.2
b.1.25
c.1.15 ††
d. 0.9
(nmol/ml)
a. 15.50±5
b. 15.20±4.70
c. 11.30±2.88
d. 9.98±3.33
(IU/g Hb)
Bober et al
2010 [29]
a.21 CKD patients
(age: 56.8±16.0 yr)
b. 21 healthy subjects
(age: 56±16.6 yr)
Plasma:
a.1.05±0.21
b.0.79±0.12
(μmol/L)
a.8.26±1.16
b. 7.26±1.50
(nmol/g Hb)
Choi et al 2011
[30]
a.16 CKD patients
GFR:23.56±10.64 ml/min/1.73 m2
b. 18 healthy subjects
(age: 48.9±15.4 yr)
a.6.3±1.5
b. 4.5±0.9
(RLU)
Sahni et al
2012 [27]
a. 60 CKD patients, (age: 43.05±11.9 yr)
GFR:12.75±5.52 ml/min
b. 85 CKD patients, (age: 42.88±11.4 yr)
GFR:28.61±12.93 ml/min
c. 40 Healthy subjects (age: 42.42±2.2 yr)
RBC :
a.4.89±1.33†
b.2.77±1.015
c. 1.13±0.219
(μmol/g Hb)
a.0.61±0.40†
b.1.05±0.334
c.1.87±0.608
(μmol/g Hb)
a.994.57±87.14 †
b.1136.99±101.56
c.1382.55±93.93
(IU)
a.125.86±17.36†
b.139.19±24.35
c. 184.66±17.29
μL/min/ml Hb)
MDA: malondialdehyde; XO: xanthine oxidase; GSH: reduced glutathione; SOD: superoxide dismutase; CAT: catalase; GPX: glutathione peroxidase; yr: years;  versus healthy controls, † difference
between a and b groups, ††difference between a and b groups with c group, ± stands for standard deviation.
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Table 2. Redox status in HD patients
Authors Groups HD modality &
period
TBARS /MDA Free sulfhydryl
groups
Isoprostanes8-
iPF2a-III
AOPP Protein
Carbonyls
XO GSH ORAC/ TEAC/
TAC
SOD/ GPx/ GR
Reductase
Haklar et al
1995 [49]
a. 14 HD patients
(age: 52 yr)
b. 14 healthy subjects
(age: 40 yr)
Cuprophan,
dialyzers,22 months,
3x/week/ 4 h
MDA(nmol/ml)
a.5.50±0.6
b.2.82±0.36
a.41.2±10.4
b.22.6±5.5
(nmol/mg
protein)
Sommerburg
et al 1998
[44]
a. 8 HD patients Hb<10 g/dl,
(age: 58 yr)
b. 8 HD patients Hb>10 g/dl,
(age: 62 yr)
c. 27 HD patients receiving
rHuEpo (age: 66 yr)
d. 20 healthy subjects
(age: 59 yr)
Bicarbonate HD, 6-
10 years,3x/week/4-
5 h
MDA (μM)
a.3.81±0.86
b.  2.77±0.58
c.  2.50±0.12
d. 0.37±0.03
Ward et al
2003 [53]
a. 11 HD patients
(age: 51± 5 yr)
b. 12-17 healthy subjects
(age 23-54 yr)
49±11 months a. 268±22
b.438±16 (μmol/ L)
a.191±27
b. 74±8
(μmol/ L)
a.0.144± 0.037
b. 0.041± 0.008
(nmol/mg)
Choi et al
[30]
a.18 patients,
age 52.0±17 yr,
b.16 healthy subjects
(age: 48.9±15.4 yr)
94.3±43.5 months,
3x/wk/4h a.
13±9.4
b. 4.5±0.9
(RLU)
Triolo et al
2003 [45]
a. 10 HD patients
(age: 64.6±13.7 yr)
b. 30 healthy subjects
(age: 59.8±9.4 yr)
Bicarbonate HD,
86.6±47.2 months,
3 x/week/3.5-4 h
MDA ( nmol/mL)
a.1.87±0.36
b. 1.13±0.18
Anraku et al
2004 [52]
a. 11 HD patients
(age 25 to 87 yr)
b.11 age-matched healthy
subjects
Bicarbonate,1- 9
years,
3 x/week/4-5 h
a. 1.0±0.1
b.0.4±0.03
(nmol/mg
protein)
Fragedaki et
al 2005 [54]
a. 12 SHD patients
(age: 57.5±12.8 yr)
b. MHD 13 patients
(age: 48±11.5 yr)
c. 12 healthy subjects
(age: 52.9±10.7 yr)
a.Polyethersulfone,
3.6±1.82 years,
3 x/week/4-4.5 h
b.Polyethersulfone,
3.3±1.37 years,
6 x/week/2-2.5 h
a.0.44±0.23
b.0.57±0.36
c. 0.60±0.46
(nmol/mg protein)
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Mera et al
2005 [51]
a. 20 HD patients
(age 62.8±12.7 yr)
b. 10 healthy subjects
(age 67.8±1.8 yr)
Bicarbonate HD,1-9
years,
3 x/week/4-5 h
a.3.12±1.1
b.2.10±0.34
(nmol/mg protein)
Stepniewska
2006 [55]
a. 25 HD patients
(age 50.3±13.79 yr)
b. 26 HD patients
(age 60.54±13.54 yr)
c.29 healthy subjects
(age 49.7±11.4 yr)
a. Polysulfone HD,
glucose-free fluid,
27.44±15.87
months,3 x/week,4h
b. Polysulfone HD,
glucose fluid,
24.43±12.68 months
3 x/week/4h
a.19.6±8.8
b.20.5±8.0
c. 14.2±2.1
(μmol/g Hb)
Gr Reductase
a.2.82±0.98
b.2.57±0.76
c. 1.95±0.40
(U/g Hb)
Dolegowska
et al 2007
[50]
a.22 HD patients
(age: 53.06±11.43 yr)
b.22 HD patients
(age: 57.70±14.78 yr)
c. 22 healthy subjects
(age: 51.93±9.94 yr)
a. Polysulfone HD.
glucose-free fluid, 3
x/week/4h
b. Polysulfone HD,
glucose fluid,3
x/week/4h
a.Plasma: 0.05±0.02
RBC: 7.19±10.45
b.Plasma:0.19±0.15
RBC:8.75±7.58
c.Plasma:0.10±0.05
RBC:5.29±7.54
(ng/ml), (ng/g Hb)
Sakata et al
2008 [46]
a.36 HD patients
(age: 63.6±12.1 yr)
b.15 healthy subjects
(age: 32.5±8.6 yr)
Bicarbonate HD,
12.1±7.0 years
MDA (μΜ)
a.0.25±0.11
b.0.05±0.02
a.88.8±39.7
b.43.8±20.3
(μΜ)
a.ORAC:
2,672±554
TEAC:
0.77±0.2
b.ORAC:
1,363±174
TEAC:
0.43±0.12
(U/ml), mM Trol
eq/l
Bober et al
2010 [29]
a.22 HD patients
(age: 55.9±14.8 yr)
b.23 HD patients
(age: 64.3±12.1 yr)
c. 21 healthy subjects
(age: 56±16.6 yr)
a. Polysulfone HD,
glucose-free fluid,
8.78±6.42 months, 3
x/week
b. Polysulfone HD
glucose fluid,
9.45±6.62 months
3x/week
MDA a.1.56±0.27
b.1.36±0.30
c.0.79±0.12
(μmol/L)
Dimitrijevic
et al  2012
[47]
a.15 HD patients
(age: 55.6±18.2 yr)
b.29 healthy subjects
(age: 55±15.8 yr)
Bicarbonate HD
52.5±61.6 months
MDA
a.Plasma:11.3±11
.2
RBC: 14.7±2.2
b.Plasma:6.0±1.1
RBC: 8.7±1.3
(mmol/l),(nmol/ml)
a.284.4±44.5
b.449.2±66.6
(μmol/ L)
a.TAC:
2.5±0.3
b. TAC:
3.6±0.5 (μmol/
L)
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TBARS: Thiobarbituric acid reactive substances; MDA: malondialdehyde; AOPP: Advanced Oxidation Protein Products; GSH: reduced glutathione; ORAC: Oxygen Radical Absorbance
Capacity; TEAC: Trolox Equivalent Antioxidant Capacity; TAC: Total Antioxidant Capacity; SOD: superoxide dismutase; GPX: glutathione peroxidase; yr: years;  versus healthy controls, ±
stands for standard deviation except in cases of studies Ward et al., 2003 and Anraku et al., 2004 where ± stands for standard error.
Guo et al
2013 [48]
a.20 HD patients
(age:55±7 yr)
b.25 healthy subjects
(age: 53±7 yr)
HD 6±1 years,
3 x/week/4 h
MDA
a.6 (median)
b. 2.9 (nmol/L)
a. GPx:
50.5±8.4
SOD::
3.4
b. GPx:
85.2±6.1 SOD::
8.3 (U/ml)
(median)
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Table 3. Redox status before and after the HD treatment
Authors Groups HD modality &
period
AOPP Ox-LDL Free
sulfhydryl
Protein
Carbonyls
TBARS
/MDA
F2-Isoprostanes GSH SOD GPx GR-
Reductase
CAT TAS
Ward et al
2003 [53]
11 HD patients,
(age 51±5 yr)
a. polysulfone
membrane
b. cellulose
membrane
49±11 months
a.190±3
7
b.163±
26
(μmol/
L)
a. 425±15
b. 408±23
(μmol/L)
a.0.175±0.03
b.0.178±0.04
(nmol/mg)
Westhuyzen
et al 2003 [75]
13 HD patients,
(age 69.2±15.6 yr)
Vitamin E
membrane, 3x/wk
a. Baseline
b. at 6 wk
c. at 13 wk
a.0.99±0.17
b.1.08±0.16
c.1.04±0.20
(mmol/L)
a.725±102
b.746±130
c.771±151
(U/g Hb)
a.46.8±14.8
b. 55.7±14.8
c. 56.7±17.2
(U/g Hb)
Trimarchi et
al 2003 [71]
12 HD patients,
(age 65.5±13.1 yr)
Cellulose
membrane, for
20.83 months,
3x/wk
4.62±0.9
(μmol/L)
Smith et al
2003 [73]
11 HD patients,
(age 64±4 yr)
Polysulfone
membrane,3x/wk
602±105 (pg/ml)
Stepniewska
et al 2006 [55]
a. 25 HD patients,
(age 50.3±13.7 yr)
b. 26 HD patients
(age 60.5±13.5 yr)
a. Polysulfone
membrane,
glucose-free fluid,
for 27.44±15.87
months,3x/week/4h
b. Polysulfone
glucose fluid,for
24.43±12.68
months 3 x/week/
4h
a.18.3±7.2
b.19.8±8.2
(mmol/gHb)
a.2.69±0.95
b.  2.05±0.59
(U/g H)
Huang et al
2006 [76]
25 HD patients,
(age 58±3yr)
HD for 12 months  0.5
(mmol/l )
Malindretos et
al 2007 [74]
20 HD patients,
(age 64.7±17.3 yr):
Polysulfone
membrane, 3x/wk/
4h
14.52±8.3
(mU/L)
Dolegowska
et al 2007 [50]
a.22 HD patients,
(age 53.1±11.4 yr)
b.22 HD patients,
a. Polysulfone
membrane,
glucose-free fluid,
a.Plasma: 0.18±0.17
RBC:7.40±11.22
b.Plasma:0.16±0.10
30
(age 57.7±14.7 yr) 3x/week/4h
b. Polysulfone
glucose fluid,
3x/week/ 4h
RBC:7.62±7.03
(ng/ml), (ng/g Hb)
Rosa Ramos
et al 2008 [72]
34 HD patients,
(age 57±1 yr)
Cellulose
membrane
0.28±0.19
(ng/g
HDL)
Bober et al
2010 [29]
a.22 HD patients,
(age 55.9±14.8 yr)
b.23 HD patients,
(age 64.3±12.1 yr)
a. Polysulfone
membrane glucose-
free fluid, 3x/week
b. Polysulfone HD
glucose
fluid,3x/week
a.2.01±0.5
5
b.1.17±0
.31
(μmol/L)
a.  8.82±2.22
b.11.07±3.28
(nmol/g Hb)
Ogunro et al
2014 [70]
a.35 HD patients,
(age 51.9±12.4 yr)
b. 38 HD patients,
(age 49.8±10.6 yr)
a. Cellulose
membrane
b. Polysulfonate
membrane,
3x/wk/ 4-5 h
a.6.05±0.9
b.
4.71±0.7
(nmol/mL
)
a. 2.09±0.3
b.3.68±0.2
(μmol/g Hb)
a.
378±13.2
b.
418±19.7
(U/g Hb)
a.22.5±3.1
b. 27.5±4.2
(U/g Hb)
a.1231±41
.6
b.1370±
39.4 (U/g
Hb)
a.1.0.±0.7
b.1.16±0.
2
(mmol/L
trolox)
AOPP: Advanced Oxidation Protein Products; Ox-LDL: oxidized Low Density Lipoprotein; MDA: malondialdehyde; GSH: reduced glutathione; SOD: superoxide dismutase; GPX: glutathione
peroxidase; CAT: Catalase; TAS: Total Antioxidant Status; yr: years; :versus before the HD treatment; : versus before the HD treatment; ± stands for standard deviation except in cases of studies of
Ward et al.,2003 and Huang et al., 2006 and Smith et al., 2003 where ± stands for standard error.
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Table 4. Other modalities of HD and redox status.
Authors Groups HD modality TBARS/MDA Protein
Carbonyls
GSSG GSH SOD GPx XO CAT TAC
Canestrari
et al 1995
[89]
a. 18 patients
(age 62.9±13.9 yr)
b. 15 healthy subjects
(age: 59.2±8.3 yr)
Peritoneal dialysis
for 26.56±23.27
months
a.  RBC: 10.8±3.8
Plasma: 74.5±20.5
b. RBC: 4.8±2.6
Plasma: 46.6±16.1
(nmol/g Hb or prot)
a.RBC:0.039±0.014
Plasma: 0.011±0.006
b.RBC 0.012±0.011
Plasma: 0.009±0.005
(μmol/g Hb or prot)
a.RBC:6.40±1.36
Plasma:  1.53±0.69
b.RBC: 4.97±0.78
Plasma:2.07±0.20
(μmol/g Hb or prot)
a.RBC:
48.7±11.5
Plasma:
5.02±1.36
b.RBC 36.1±8.5
Plasma:
5.50±0.79 (U/g
Hb or prot)
Choi et al
2011[30]
a. 18 patients
(age 48.1±16.4 yr)
b. 18 patients
(age 52.0±17 yr)
c.16 healthy subjects
(age 48.9±15.4 yr)
a. Peritoneal
dialysis (PD) for
99.8±39.4 months,
1.7x/wk
b. Typical HD for
94.3±43.5 months,
3x/wk
a.12.2±3.5
b. 13.0±9.4
c.4.5±0.9
(RLU)
Gonzalez –
Diez et al
2012 [90]
a. 25 patients
b. 15 patients
(age: -)
a.
Haemodialfiltration
(HFR) for 1 year
b. HD with
polysulfone
membrane for 1
year
a.~19
b. ~17 (μΜ)
a. ~2.2 b.~
2.2
(nmol/mg
prot)
a.~1
b.~ 0.9
(μmoles/g)
a.~2100
b. ~1400
(U/g prot)
a.~42
b.~34 (U/g prot)
a. ~18
b. ~25
(U/g
prot)
a. ~4
b. ~4
(mM
Trolox)
TBARS: Thiobarbituric acid reactive substances ; Ox-LDL: oxidized Low Density Lipoprotein ;GSSG: oxidized glutathione; GSH: reduced glutathione ; SOD: superoxide dismutase ; GPx: glutathione peroxidase ;
XO:Xanthine Oxidase ; CAT:Catalase ; TAC:Total Antioxidant Capacity; yr: years; : versus healthy, : versus healthy, ~: values were estimated according to figures, ± stands for standard deviation.
